Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-13
2005-12-13
Page, Thurman K. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C424S400000, C424S439000, C424S451000, C424S464000, C424S489000
Reexamination Certificate
active
06974816
ABSTRACT:
The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.
REFERENCES:
patent: 2 332 373 (1999-06-01), None
patent: 99/03854 (1999-01-01), None
patent: 00/24412 (2000-05-01), None
Takayuki Asahara et al., “Local Delivery of Vascular Endothelial Growth Factor Accelerates Reendothelialization and Attenuates Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery” Circulation, vol. 91(11), pp. 2793-2801 (1995).
Mikko O. Hiltunen et al., “Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta” Circulation, vol. 102, pp. 2262-2268 (2000).
Olli Leppänen et al., “Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model” Arterioscler Thromb Vasc Biol., vol. 20, pp. e89-e95 (2000).
M. Myllärniemi, “Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo,” Cardiovascular Drugs and Therapy, vol. 13, pp. 159-168 (1999).
Alitalo Kari
Heldin Carl-Henrik
Leppänen Olli
Östman Arne
Ylä-Herttuala Seppo
Dohmann George R.
Jackson Oona A.
Licentia Ltd.
Ludwig Institiute for Cancer Research
Oh Simon J.
LandOfFree
Combination for the treatment of endothelial damage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination for the treatment of endothelial damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination for the treatment of endothelial damage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501934